Let's look at what the actual Package Insert for this product says it’s supposed to do as that contains the officially approved claims about the product.
The first official claim is that it PREVENTS COVID-19 Disease.
COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
It does not claim to reduce the relative risk of “severe” disease or hospitalization. The vast majority of cases of COVID-19 disease are mild or moderate and require no hospitalization or any special care other than staying home and resting. This product was unambiguously marketed to prevent this common type of disease as well.
Of course “prevention” usually doesn’t mean 100% risk reduction against infection, but somewhere in the ball park of 90–95% relative risk reduction of infection compared to abstaining from the intervention. This product claims a 95% efficacy based on the 162 to 8 case load split between the placebo and intervention groups in the initial clinical trials.
For participants without evidence of SARS-CoV-2 infection prior to 7 days after Dose 2, vaccine efficacy against confirmed COVID-19 occurring at least 7 days after Dose 2 was 95.0% (95% credible interval: 90.3, 97.6), which met the pre-specified success criterion. The case split was 8 COVID-19 cases in the COMIRNATY group compared to 162 COVID-19 cases in the placebo group.
We now have an assload of real world evidence that the Comirnaty efficacy against infection variants in circulation is nowhere near 95%. It does not even meet the 50% efficacy threshold of the WHO and what little remaining efficacy it has in reducing the risk of infection and symptomatic disease is very short lived only lasting for a few months.
Which is More Effective in Preventing COVID19?
We also have an increasing body of evidence that efficacy doesn’t just become negligible after 6 months but that repeated booster recipients develop immune tolerance 6 months after their last booster becoming more likely to be reinfected. You won’t find this on the package insert nor the now well documented immune imprinting of antibodies for the wild-type variant that ceased circulation four years ago.
What Makes modRNA COVID19 Vaccines so Effective?
How many COVID19 Shots Do you Need to Become Immune to COVID19